Intellia Therapeutics (NTLA) EBT Margin (2015 - 2026)
Intellia Therapeutics' (NTLA) quarterly EBT Margin came in at 1277.02% in Q1 2026, up 25623.0% year-on-year from N/an in Q1 2025, and down 218.51% on a QoQ basis from 400.94% in Q4 2025.
Intellia Therapeutics (NTLA) EBT Margin (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of EBT Margin data on file, last reported at 1277.02% in Q1 2026.
- On a quarterly basis, EBT Margin rose 25623.0% year-over-year to 1277.02% in Q1 2026; TTM through Mar 2026 was 945.8%, a 51960.0% increase from a year earlier, with the FY2025 full-year figure at 1960.12%, up 23361.0% from the prior year.
- EBT Margin for Q1 2026 stood at 1277.02%, down from 400.94% in the prior quarter.
- Over the last five years, EBT Margin for NTLA reached as high as 8521.39% in Q4 2023 and fell as low as 3097.89% in Q1 2022.
- Historically, EBT Margin has averaged 774.62% across 5 years, with a median of 1319.11% in 2023.
- Across the five-year window, EBT Margin surged 1447721 bps in 2022 and tumbled 950394 bps in 2024, its largest moves.
- Year by year, EBT Margin stood at 799.79% in 2022, then jumped by 1165 bps to 8521.39% in 2023, then tumbled by 112 bps to 982.55% in 2024, then surged by 59 bps to 400.94% in 2025, then plunged by 219 bps to 1277.02% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 1277.02% in Q1 2026, 400.94% in Q4 2025, and 1613.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Intellia Therapeutics | 1.32 Bn | 1.32 Bn | - | -1,277.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,277.02% |
| Dec 31, 2025 | -400.94% |
| Sep 30, 2025 | -1,613.80% |
| Jun 30, 2025 | -829.98% |
| Mar 31, 2025 | -1,533.25% |
| Dec 31, 2024 | -982.55% |
| Sep 30, 2024 | -1,579.39% |
| Jun 30, 2024 | -2,047.45% |
| Mar 31, 2024 | -445.81% |
| Dec 31, 2023 | 8,521.39% |
| Sep 30, 2023 | -1,319.11% |
| Jun 30, 2023 | -1,385.28% |
| Mar 31, 2023 | -1,264.14% |
| Dec 31, 2022 | -799.79% |
| Sep 30, 2022 | -1,662.81% |
| Jun 30, 2022 | -1,450.67% |
| Mar 31, 2022 | -3,097.89% |
| Dec 31, 2021 | -638.22% |
| Sep 30, 2021 | -9,349.96% |
| Jun 30, 2021 | -15,927.88% |